|
Market Closed -
Oslo Bors
18:45:00 31/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 2.980 NOK | +6.62% |
|
+11.19% | -56.11% |
| 08-28 | Elliptic Laboratories Books First Order for Smart Wearables | MT |
| 08-27 | Elliptic Laboratories ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Projected Income Statement: Elliptic Laboratories ASA
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 63.04 | 52.06 | 68.32 | 131.9 | 102.7 | 99.54 | 120.3 | 150 |
| Change | - | -17.41% | 31.23% | 93.08% | -22.12% | -3.11% | 20.83% | 24.7% |
| EBITDA 1 | -2.829 | -30.81 | -33.52 | 25.12 | -20.68 | -0.8894 | 17.36 | 35.89 |
| Change | - | -989.22% | -8.78% | 174.94% | -182.33% | 95.7% | 2,052.18% | 106.72% |
| EBIT 1 | -11.14 | -42.13 | -49.74 | 4.71 | -45.44 | -26.28 | -8.055 | 8.765 |
| Change | - | -278.2% | -18.07% | 109.47% | -1,064.84% | 42.17% | 69.35% | 208.81% |
| Interest Paid | -5.683 | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -13.09 | -39.3 | -46.86 | 17.05 | -58.24 | -35 | -7.729 | 8.709 |
| Change | - | -200.18% | -19.22% | 136.38% | -441.61% | 39.9% | 77.92% | 212.68% |
| Net income 1 | -11.16 | -32.04 | -37.85 | 8.96 | -139 | -30.08 | -6.028 | 6.793 |
| Change | - | -187.2% | -18.13% | 123.67% | -1,651.36% | 78.36% | 79.96% | 212.68% |
| Announcement Date | 10/03/22 | 17/02/23 | 15/02/24 | 27/02/25 | 26/02/26 | - | - | - |
1NOK in Million
Estimates
Forecast Balance Sheet: Elliptic Laboratories ASA
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | -201 | -166 | -89.7 | -57 | -43.1 | -65.8 | -48.6 | -43.2 |
| Change | - | 17.41% | 45.96% | 36.45% | 24.39% | -52.82% | 26.14% | 11.11% |
| Announcement Date | 10/03/22 | 17/02/23 | 15/02/24 | 27/02/25 | 26/02/26 | - | - | - |
1NOK in Million
Estimates
Cash Flow Forecast: Elliptic Laboratories ASA
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| CAPEX 1 | 17.61 | 23.33 | 25.48 | 30.72 | 29.08 | 22 | 24 | 26 |
| Change | - | 32.46% | 9.22% | 20.56% | -5.32% | -24.35% | 9.09% | 8.33% |
| Free Cash Flow (FCF) 1 | -28.43 | -36.08 | - | - | -23.09 | -27 | -11 | 2 |
| Change | - | -26.91% | - | - | - | -16.94% | 59.26% | 118.18% |
| Announcement Date | 10/03/22 | 17/02/23 | 15/02/24 | 27/02/25 | 26/02/26 | - | - | - |
1NOK in Million
Estimates
Forecast Financial Ratios: Elliptic Laboratories ASA
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
| EBITDA Margin (%) | -4.49% | -59.19% | -49.06% | 19.04% | -20.13% | -0.89% | 14.43% | 23.93% |
| EBIT Margin (%) | -17.67% | -80.92% | -72.81% | 3.57% | -44.23% | -26.4% | -6.7% | 5.84% |
| EBT Margin (%) | -20.77% | -75.49% | -68.58% | 12.92% | -56.68% | -35.16% | -6.43% | 5.81% |
| Net margin (%) | -17.7% | -61.54% | -55.4% | 6.79% | -135.3% | -30.22% | -5.01% | 4.53% |
| FCF margin (%) | -45.11% | -69.31% | - | - | -22.47% | -27.12% | -9.15% | 1.33% |
| FCF / Net Income (%) | 254.87% | 112.62% | - | - | 16.61% | 89.75% | 182.47% | 29.44% |
Profitability | ||||||||
| ROA | - | - | - | - | - | - | - | - |
| ROE | -4.2% | -9.7% | -11.96% | 2.84% | -54.86% | - | - | 3.09% |
Financial Health | ||||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Debt / Free cash flow | - | - | - | - | - | - | - | - |
Capital Intensity | ||||||||
| CAPEX / Current Assets (%) | 27.94% | 44.81% | 37.29% | 23.28% | 28.31% | 22.1% | 19.95% | 17.33% |
| CAPEX / EBITDA (%) | -622.48% | -75.7% | -76.01% | 122.29% | -140.63% | -2,473.72% | 138.24% | 72.44% |
| CAPEX / FCF (%) | -61.94% | -64.64% | - | - | -125.96% | -81.48% | -218.18% | 1,300% |
Items per share | ||||||||
| Cash flow per share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Dividend per Share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Book Value Per Share 1 | 3.301 | 3.134 | 2.929 | 3.09 | 1.786 | 1.667 | 1.633 | 1.697 |
| Change | - | -5.06% | -6.53% | 5.5% | -42.22% | -6.64% | -2.03% | 3.88% |
| EPS 1 | -0.11 | -0.31 | -0.36 | 0.09 | -1.32 | -0.2313 | -0.0458 | 0.0511 |
| Change | - | -181.82% | -16.13% | 125% | -1,566.67% | 82.48% | 80.18% | 211.45% |
| Nbr of stocks (in thousands) | 103,842 | 104,074 | 104,838 | 105,275 | 105,287 | 126,337 | 126,337 | 126,337 |
| Announcement Date | 10/03/22 | 17/02/23 | 15/02/24 | 27/02/25 | 26/02/26 | - | - | - |
1NOK
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E | -12.1x | -61x |
| PBR | 1.68x | 1.71x |
| EV / Sales | 2.89x | 2.53x |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Year-on-year evolution of the Yield
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.795NOK
Average target price
4.800NOK
Spread / Average Target
+71.74%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ELABS Stock
- Financials Elliptic Laboratories ASA
Select your edition
All financial news and data tailored to specific country editions
